Cyclacel Pharmaceuticals (NASDAQ:BGMS) and MSC Industrial Direct (NYSE:MSM) Head-To-Head Analysis

MSC Industrial Direct (NYSE:MSM) and Cyclacel Pharmaceuticals (NASDAQ:BGMS) are both industrials companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, valuation, profitability, risk, dividends, earnings and institutional ownership.

Institutional and Insider Ownership

79.3% of MSC Industrial Direct shares are owned by institutional investors. Comparatively, 23.6% of Cyclacel Pharmaceuticals shares are owned by institutional investors. 19.0% of MSC Industrial Direct shares are owned by insiders. Comparatively, 23.7% of Cyclacel Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Profitability

This table compares MSC Industrial Direct and Cyclacel Pharmaceuticals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
MSC Industrial Direct	5.91%	17.34%	9.79%
Cyclacel Pharmaceuticals	-118.27%	-31.60%	-27.72%

Valuation and Earnings

This table compares MSC Industrial Direct and Cyclacel Pharmaceuticals”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MSC Industrial Direct	$3.77 billion	1.80	$199.33 million	$4.14	29.32
Cyclacel Pharmaceuticals	$750,000.00	6.62	-$3.00 million	($3.64)	-0.25

MSC Industrial Direct has higher revenue and earnings than Cyclacel Pharmaceuticals. Cyclacel Pharmaceuticals is trading at a lower price-to-earnings ratio than MSC Industrial Direct, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of current ratings and price targets for MSC Industrial Direct and Cyclacel Pharmaceuticals, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MSC Industrial Direct	0	4	4	0	2.50
Cyclacel Pharmaceuticals	1	0	0	0	1.00

MSC Industrial Direct presently has a consensus target price of $123.43, indicating a potential upside of 1.69%. Given MSC Industrial Direct’s stronger consensus rating and higher possible upside, analysts plainly believe MSC Industrial Direct is more favorable than Cyclacel Pharmaceuticals.

Risk and Volatility

MSC Industrial Direct has a beta of 0.83, suggesting that its stock price is 17% less volatile than the S&P 500. Comparatively, Cyclacel Pharmaceuticals has a beta of -0.4, suggesting that its stock price is 140% less volatile than the S&P 500.

Summary

MSC Industrial Direct beats Cyclacel Pharmaceuticals on 12 of the 14 factors compared between the two stocks.

About MSC Industrial Direct

MSC Industrial Direct Co., Inc., together with its subsidiaries, distributes metalworking and maintenance, repair, and operations (MRO) products and services in the United States, Canada, Mexico, the United Kingdom, and internationally. The company's MRO products include cutting tools, measuring instruments, tooling components, metalworking products, fasteners, flat stock products, raw materials, abrasives, machinery hand and power tools, safety and janitorial supplies, plumbing supplies, materials handling products, power transmission components, and electrical supplies. It offers stock-keeping units through its catalogs and brochures; e-commerce channels, including its website, mscdirect.com; inventory management solutions; and customer care centers, customer fulfillment centers, regional inventory centers, and warehouses. The company serves individual machine shops, manufacturing companies, and government agencies. MSC Industrial Direct Co., Inc. was founded in 1941 and is headquartered in Melville, New York.

About Cyclacel Pharmaceuticals

Cyclacel Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases. The company’s development programs include fadraciclib, a cyclin dependent kinase Inhibitors (CDK) that is in Phase 1/2 clinical trial for the treatment of solid tumors, as well as in combination with venetoclax to treat relapsed or refractory chronic lymphocytic leukemia; and CYC140, a polo-like kinase inhibitor program, which is in Phase 1/2 clinical trial for the treatment of advanced leukemias and solid tumors. Its development programs also comprise Sapacitabine, a novel nucleoside analog that is orally available prodrug of CNDAC, which is in Phase 1/2 clinical trials to treat acute myeloid leukemia and myelodysplastic syndrome; and seliciclib, a CDK inhibitor that is in Phase 2 investigator-sponsored trials (IST) for Cushing’s disease, as well as in Phase 1/2 IST for the treatment for advanced rheumatoid arthritis. The company has a clinical collaboration agreement with the University of Texas MD Anderson Cancer Center to clinically evaluate the safety and efficacy of three cyclacel medicines in patients with hematological malignancies, including chronic lymphocytic leukemias, acute myeloid leukemias, myelodysplastic syndromes, and other advanced leukemias. Cyclacel Pharmaceuticals, Inc. is headquartered in Berkeley Heights, New Jersey.